Figure 2.

Dose–response curve for inhibition of acute TA-TMA patient plasma-mediated caspase 8 activation in MVEC in vitro. Cultures of primary human neonatal dermal microvascular endothelial cells (MVEC) were exposed to pooled plasma (2% v/v) from three patients with acute TA-TMA in the presence of varying concentrations of narsoplimab. Caspase 8 activity was analyzed in cell lysates after 5 h of incubation. Dotted and dashed lines represent caspase activity in cultures exposed to pooled plasma from healthy individuals or allogeneic hematopoietic stem cell patients who did not develop a TMA, respectively.